US/UK/Canada

Share

Contacts

  • Medicover
    P.O. Box 5283 SE-102 46 Stockholm, Sweden Visiting address: Riddargatan 12A, Stockholm, Sweden
    http://www.medicover.com

    • Links

    Pick a time period -
    Tags ( Active)

    Year-end report January–December 2024

    Fourth quarter · Revenue amounted to €555.8m (€461.9m), an increase of 20.3% with an organic growth of 18.6%. · Operating profit (EBIT) was €23.3m (€19.0m), representing an operating margin of 4.2% (4.1%). · Net profit amounted to €7.4m (€8.6m), which represents a margin of 1.3% (1.9%). · EBITDA was €73.2m (€66.4m), an increase of 10.2%. EBITDA margin was 13.2% (14.4%). · EBITDAaL amounted to €44.0m (€40.8m), an increase by 7.8%, corresponding to an EBITDAaL margin of 7.9% (8.8%). · Net cash flow from operating activities was €64.2m (€42.5m). · Basic/diluted earnings

    John Stubbington appointed new CEO of Medicover from 1 May 2025

    The Board of Directors of Medicover AB (publ) (“Medicover”) today announces that John Stubbington will succeed Fredrik Rågmark as new CEO of the Medicover group from 1 May 2025.After 30 years with the Medicover group and 25 years as CEO, Fredrik Rågmark will step down from his operational role in Medicover by the end of April 2025 but will remain available to Medicover during 2025. “On behalf of the board and the company, I would like to thank Fredrik for his exceptional contribution to the development of Medicover and outstanding leadership of Medicover through all these years. Fredrik

    Invitation to Medicover’s results presentation for Q4 2024

    Medicover’s (MCOV B) year-end and Q4 report 2024 will be published on 12 February at 07.45 CET. The Company will hold a conference call (in English) for media, financial analysts and investors at 09.30 CET. The report will be presented by CEO Fredrik Rågmark and CFO Anand Patel, followed by a Q&A session. Shortly before the webcast, presentation slides will be available on medicover.com . If you wish to participate via audiocast please use the link below. Audiocast 

    Medicover to exit Hungary fully

    Medicover has decided to exit the Hungarian market and disposes of its insurance operations in Hungary. Since 2013, Medicover has only operated its health insurance business in Hungary having no clinics or health provision activities. Medicover will also terminate its brand licensing used with Hungarian partner clinics providing services to members. The health insurance business will be transferred to another Hungarian health insurer and a transfer process has already been initiated in collaboration with the relevant authorities. The transition is expected to take approximately six

    Medicover’s Social Finance Investor Report is now published

    Medicover has released its Social Finance Investor Report for 2024. The social finance framework was launched in 2021 and in connection with the launch €277m was raised in German schuldschein debt. The social financing framework is a use-of-proceeds structure and aims to contribute to the World Bank’s Universal Health Coverage goals, ensuring that people have access to essential healthcare services. Lack of health infrastructure is one of the global development challenges and improving and increasing access for communities to affordable healthcare requires significant investments in

    Medicover to evaluate a potential separate listing in india

    The board of directors of Medicover AB (Publ) has today decided to evaluate the opportunity to list the Indian hospital subsidiary in India over the coming 12-24 months to further support its growth ambitions in the fast-growing Indian market.Medicover Hospitals India operates 23 hospitals and 2 cancer centres in four states (Andra Pradesh, Karnataka, Maharashtra and Telangana). Revenue in India for the last twelve months was €196.9 million at the end of Q3 2024. Medicover plans to open two new hospitals in 2025 and early 2026. If a listing takes place, the process is estimated to take

    Interim report July–September 2024

    Third quarter · Revenue amounted to €527.8m (€440.5m), an increase of 19.8% with an organic growth of 17.4%. · Operating profit (EBIT) was €6.7m (€18.5m), representing an operating margin of 1.3% (4.2%), impacted by an impairment charge of €-16.4m. · Net result amounted to €-5.2m (€0.5m), which represents a margin of -1.0% (0.1%). · EBITDA was €73.9m (€64.8m), an increase of 14.1%. EBITDA margin was 14.0% (14.7%). · EBITDAaL amounted to €45.1m (€39.6m), an increase by 13.8%, corresponding to an EBITDAaL margin of 8.6% (9.0%). · Net cash flow from operating activities was

    Invitation to Medicover’s results presentation for Q3 2024

    Medicover’s (MCOV B) Q3 report 2024 will be published on 30 October at 07.45 CET. The Company will hold a conference call (in English) for media, financial analysts and investors at 09.30 CET. The report will be presented by CEO Fredrik Rågmark, CFO Joe Ryan and successor Anand Patel, followed by a Q&A session. Shortly before the webcast, presentation slides will be available on medicover.com . If you wish to participate via audiocast please use the link below. Audiocast 

    Medicover’s nomination committee for the AGM 2025

    Medicover AB (publ) (“Medicover”) publishes the nomination committee’s composition for the annual general meeting (“AGM”) in 2025. The nomination committee, which is appointed in accordance with the principles adopted by the annual general meeting on 26 April 2024, consists of: · Fredrik Stenmo, representing Celox Holding AB and the Christina af Jochnick family’s total shareholding · Hans Ramel, NG Invest Beta AB · Jannis Kitsakis, Fjärde AP-Fonden · Sophie Larsén, AMF och AMF Fonder   The Board of Medicover AB (publ)   For more information, please visit:

    Anand Patel new Chief Financial Officer of Medicover

    Medicover AB (publ) has signed a letter of intent with Anand Patel to join Medicover as the Chief Financial Officer (CFO) and member of the Executive Management Team. Anand will join Medicover from October 1, 2024, with the handover of the role during Q4 2024. Anand Patel has developed his career in the retail sector, where he has held international finance and business management positions and has extensive experience from Polish and Central- East Europe markets. He has served as the CFO and managing director of Pepco, a rapidly expanding international retail chain – one of the leading

    Interim report April–June 2024

    Second quarter · Revenue amounted to €509.4m (€424.7m), an increase of 20.0% with an organic growth of 16.5%. · Operating profit (EBIT) was €21.3m (€13.2m), an increase of 61.4%, representing an operating margin of 4.2% (3.1%). · Net profit amounted to €5.9m (€7.2m), which represents a margin of 1.2% (1.7%). · EBITDA was €70.6m (€58.3m), an increase of 21.1%. EBITDA margin was 13.8% (13.7%). · EBITDAaL amounted to €43.3m (€33.9m), an increase by 27.9%, corresponding to an EBITDAaL margin of 8.5% (8.0%). · Net cash flow from operating activities was €47.4m (€43.6m). ·

    Invitation to Medicover’s results presentation for Q2 2024

    Medicover’s (MCOV B) Q2 report 2024 will be published on 25 July at 07.45 CEST. The Company will hold a conference call (in English) for media, financial analysts and investors at 09.30 CEST. The report will be presented by CEO Fredrik Rågmark and CFO Joe Ryan and followed by a question-and-answer session. Shortly before the webcast, presentation slides will be available on medicover.com . To access live webcast register here . To dial in and ask questions register here (

    Number of shares and votes in Medicover

    The number of shares and votes in Medicover AB (publ) (“Medicover ” or the “company”) has changed as a result of conversions of in total 33,300 class A shares into B shares carried out in April following requests from shareholders in accordance with the conversion clause in Medicover’s articles of association. Today, the last trading day of the month, there are in total 153,535,195 shares in Medicover, of which 76,631,101 are class A shares, together carrying 76,631,101 votes, 73,021,272 are class B shares, together carrying 7,302,127.2 votes and 3,882,822 are

    Bulletin from annual general meeting in Medicover AB (publ)

    The below resolutions were passed at Medicover’s annual general meeting (the “AGM”) held today on 26 April 2024. Election of the board of directors and auditor The AGM resolved, in accordance with the proposal from the nomination committee, that the number of board members appointed by the shareholders’ meeting shall be nine. Fredrik Stenmo, Peder af Jochnick, Anne Berner, Arno Bohn, Sonali Chandmal, Michael Flemming, Margareta Nordenvall, Fredrik Rågmark and Azita Shariati were re-elected as board members. Fredrik Stenmo was re-elected as the chairman of the board. The AGM resolved

    Interim report January–March 2024

    · Revenue amounted to €498.8m (€419.3m), an increase of 18.9% with an organic growth of 14.2%. · Operating profit (EBIT) was €19.0m (€10.7m), an increase of 78.0%, representing an operating margin of 3.8% (2.6%). · Net profit amounted to €6.5m (€2.1m), which represents a margin of 1.3% (0.5%). · EBITDA was €67.2m (€54.3m), an increase of 23.9%. EBITDA margin was 13.5% (12.9%). · EBITDAaL amounted to €40.6m (€30.6m), an increase by 32.8%, corresponding to an EBITDAaL margin of 8.1% (7.3%). · Net cash flow from operating activities was €78.5m (€61.4m). · Basic/diluted

    Invitation to Medicover’s results presentation for Q1 2024

    Medicover’s (MCOV B ) Q1 report 2024 will be published on 26 April at 07.45 CEST. The Company will hold a conference call (in English) for media, financial analysts and investors at 09.30 CEST. The report will be presented by CEO Fredrik Rågmark and CFO Joe Ryan and followed by a question-and-answer session. Shortly before the webcast, presentation slides will be available on medicover.com . To access live webcast register here . To dial in and ask questions

    Medicover’s Annual Report for 2023 is published

    Medicover’s annual report including sustainability report for 2023 has today been published and is now available on the company’s website medicover.com . The annual report is also attached to this press release. For further information, please contact:Hanna Bjellquist, Head of Investor Relations+46 703 033 272hanna.bjellquist@medicover.com This information is information that Medicover AB (publ) is obliged to make public pursuant to the Securities Markets Act. The information was submitted for publication

    Notice of annual general meeting of Medicover AB (publ)

    The shareholders of Medicover AB (publ), with registered office in Stockholm and corporate registration number 559073-9487, are summoned to the annual general meeting on Friday 26 April 2024 at 1.00 p.m. at Advokatfirman Vinge’s premises at Smålandsgatan 20, SE-111 46 Stockholm, Sweden. Registration starts at 12.30 p.m. Right to participate in the annual general meeting There are two ways for shareholders to participate in the annual general meeting: (i) participating at the venue, or (ii) participating through advance voting. In either case, if the shares are registered in the name

    Year-end report January–December 2023

    Fourth quarter · Revenue amounted to €461.9m (€397.7m), an increase of 16.1% with an organic growth of 13.5%. · Operating profit (EBIT) was €19.0m (€8.9m), an increase of 117.2%, representing an operating margin of 4.1% (2.2%). · Net profit amounted to €8.6m (€2.3m), which represents a margin of 1.9% (0.6%). · EBITDA was €66.4m (€53.2m), an increase of 25.3%. EBITDA margin was 14.4% (13.3%). · EBITDAaL amounted to €40.8m (€30.1m), an increase by 36.1%, corresponding to an EBITDAaL margin of 8.8% (7.5%). · Net cash flow from operating activities was €42.5m (€41.2m). ·

    Number of shares and votes in Medicover

    The number of shares and votes in Medicover AB (publ) (“Medicover” or the “company”) has changed as a result of conversions of in total 6,975 class A shares into B shares carried out in January following requests from shareholders in accordance with the conversion clause in Medicover’s articles of association. Today, the last trading day of the month, there are in total 153,535,195 shares in Medicover, of which 76,664,401 are class A shares, together carrying 76,664,401 votes, 72,987,972 are class B shares, together carrying 7,298,797.2 votes and 3,882,822 are class C shares, together

    Invitation to Medicover’s results presentation for Q4 2023

    Medicover’s (MCOV B) year-end and Q4 report 2023 will be published on 9 February at 07.45 CET. The Company will hold a conference call (in English) for media, financial analysts, and investors at 09.30 CET. The report will be presented by CEO Fredrik Rågmark and CFO Joe Ryan and followed by a question-and-answer session. Shortly before the webcast, presentation slides will be available on medicover.com . To access live webcast, register here . To dial in and ask questions register here

    Medicover expands lab network in Berlin

    Medicover acquires the IFLB Group in Berlin. IFLB Group consists of two lab sites and two clinics and approximately 150 employees. Revenue for 2023 is estimated at €15 million. The acquisition will be consolidated from January 2024. The acquisition includes a newly constructed 3,600 m[2] lab site in the Berlin area which will complement Medicover’s network in the area enabling streamlining of some lab processes with efficiency improvements. “We are pleased to welcome the employees of IFLB Group and their expertise to Medicover. The acquisition is synergistic with our business and

    Kamila Skorupiński new Chief People Officer as of 1 April 2024

    Kamila Skorupiński will assume the role of Group Chief People Officer as of 1 April 2024 and be part of the executive management team. Kamila joined Medicover in January 2018, and since then, she has been HR Director for Healthcare Services. “Kamila is an experienced HR Manager, with valuable experience from large global companies. Since joining Medicover, Kamila has successfully transformed the HR function within Healthcare Services to support business growth and navigate the organisation through last years’ disruptions. Kamila is a good fit for the role, and human resources is a key

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media